Company Overview
Fractyl Health, Inc. operates as a metabolic therapeutics company dedicated to developing therapies for the treatment of type 2 diabetes and obesity, specifically focusing on the Revita DMR System, an outpatient procedural therapy designed to durably modify duodenal dysfunction. The company functions within the Healthcare sector and the Biotechnology industry, a classification that typically denotes a focus on early-stage research, development, and commercialization of novel medical technologies rather than mature manufacturing or service delivery. The firm's current market capitalization stands at $71.17M, while its annual revenue and employee count are not publicly disclosed in the available financial data. This valuation indicates that the company is a small-cap entity operating with limited historical revenue data, suggesting it is in a growth or development phase where market value is derived primarily from pipeline potential rather than established cash flow generation.
Financial Health
The company's financial performance over the trailing twelve months shows a revenue figure that is not disclosed, alongside a net income loss of $-140,954,000 and an EBITDA of $-95,687,000. The significant gap between the non-disclosed revenue and the substantial net income loss reveals a cost structure characterized by high operating expenses, likely driven by research and development activities, clinical trial costs, and general administrative overhead typical of a biotechnology firm in the development stage. Free cash flow stands at $-56,585,000, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating surplus liquidity for shareholder distributions or significant debt repayment. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet achieved profitability or that its financial reporting structure does not reflect positive margins in the current period. The company holds $81.54M in cash against $61.65M in debt, resulting in a debt-to-equity ratio of 651.79, which suggests a highly leveraged balance sheet relative to its equity base, though the absolute debt level is partially offset by substantial cash reserves. The current ratio is 4.78, a metric that indicates strong short-term liquidity and the ability to cover its short-term obligations more than four times over with its available current assets. Return on Equity is -744.2% and Return on Assets is -52.7%, metrics that reveal that management effectiveness in generating profit relative to the capital employed is currently negative, reflecting the inherent losses associated with the company's current operational phase.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is -0.79, implying that the market anticipates continued negative earnings in the near future rather than a transition to profitability in the immediate term. The price-to-book ratio is 7.24, indicating that the market is valuing the company at a significant premium over its book value, which often reflects investor confidence in the intangible value of the company's drug pipeline and proprietary technology rather than its tangible assets. The price-to-sales ratio and EV/EBITDA are not available or are negative (-0.54 for EV/EBITDA), suggesting that traditional valuation multiples are not applicable in a standard sense for a loss-making biotechnology company, and investors must rely on alternative metrics like market cap and pipeline potential to assess value. The 52-week high is $3.03 and the 52-week low is $0.38, meaning the stock is currently trading within a wide volatility range defined by these bounds. The beta value is 1.51, which indicates that the stock's price volatility is significantly higher than the broader market, moving approximately 51% more than the market index during periods of price fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the absence of these figures underscores the speculative nature of the investment based on future clinical outcomes rather than historical expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available resources, including its cash reserves, back into research, development, and operational expansion rather than distributing income to shareholders. This approach is standard for biotechnology companies in the development phase, where capital preservation and investment in the Revita DMR System are prioritized over income generation for investors seeking current yield. The overall growth and income profile is characterized by a reliance on future clinical milestones and regulatory approvals to drive value, rather than current cash flow or dividend income, creating a high-risk, high-potential-return dynamic typical of the biotechnology sector.